scholarly journals Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies

2020 ◽  
Vol 40 (10) ◽  
pp. 2385-2393 ◽  
Author(s):  
Betty B. Yao ◽  
Linda M. Fredrick ◽  
Gretja Schnell ◽  
Kris V. Kowdley ◽  
Paul Y. Kwo ◽  
...  
Keyword(s):  
Integrated Analysis ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Hcv Genotype ◽  
Genotype 5

THU-194-Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: An integrated analysis of phase 2 and 3 studies

2019 ◽  
Vol 70 (1) ◽  
pp. e248
Author(s):  
Betty Yao ◽  
Tarik Asselah ◽  
Linda Fredrick ◽  
Gretja Schnell ◽  
Kris V. Kowdley ◽  
...  
Keyword(s):  
Integrated Analysis ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Hcv Genotype ◽  
Genotype 5

Mo1389 - Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with HCV Genotype 5 or 6 Infection: The Endurance-5,6 Study

2018 ◽  
Vol 154 (6) ◽  
pp. S-1190-S-1191
Author(s):  
Tarik Asselah ◽  
Tram T. Tran ◽  
Katia Alves ◽  
Tuan T. Nguyen ◽  
Florence Wong ◽  
...  
Keyword(s):  
Efficacy And Safety ◽  
Hcv Genotype ◽  
Genotype 5

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with HCV Genotype 5 or 6 Infection: The ENDURANCE-5,6 Study

2018 ◽  
Vol 68 ◽  
pp. S39 ◽  
Author(s):  
T. Asselah ◽  
T. Tran ◽  
K. Alves ◽  
T. Nguyen ◽  
F. Wong ◽  
...  
Keyword(s):  
Efficacy And Safety ◽  
Hcv Genotype ◽  
Genotype 5

scholarly journals Efficacy and safety of the selective progesterone receptor modulator (PRM) vilaprisan: integrated analysis of phase 2 asteroid 1 and 2 studies

2018 ◽  
Vol 110 (4) ◽  
pp. e135 ◽  
Author(s):  
K. Gemzell Danielsson ◽  
L.D. Bradley ◽  
C. Ahlers ◽  
T. Faustmann ◽  
K. Petersdorf ◽  
...  
Keyword(s):  
Progesterone Receptor ◽  
Integrated Analysis ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Receptor Modulator
Sign in / Sign up

Export Citation Format

Share Document